OXYMETAZOLINE HYDROCHLORIDE - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for oxymetazoline hydrochloride and what is the scope of patent protection?
Oxymetazoline hydrochloride
is the generic ingredient in six branded drugs marketed by Taro, Mayne Pharma, Bayer Healthcare Llc, Rvl Pharms, Johnson And Johnson, and St Renatus, and is included in six NDAs. There are twenty-two patents protecting this compound. Additional information is available in the individual branded drug profile pages.Oxymetazoline hydrochloride has seventy-five patent family members in thirty countries.
There is one drug master file entry for oxymetazoline hydrochloride. Four suppliers are listed for this compound.
Summary for OXYMETAZOLINE HYDROCHLORIDE
International Patents: | 75 |
US Patents: | 22 |
Tradenames: | 6 |
Applicants: | 6 |
NDAs: | 6 |
Drug Master File Entries: | 1 |
Finished Product Suppliers / Packagers: | 4 |
Raw Ingredient (Bulk) Api Vendors: | 68 |
Clinical Trials: | 51 |
Patent Applications: | 3,217 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for OXYMETAZOLINE HYDROCHLORIDE |
What excipients (inactive ingredients) are in OXYMETAZOLINE HYDROCHLORIDE? | OXYMETAZOLINE HYDROCHLORIDE excipients list |
DailyMed Link: | OXYMETAZOLINE HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for OXYMETAZOLINE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Milton S. Hershey Medical Center | Phase 3 |
Rigshospitalet, Denmark | Phase 4 |
University of Alabama at Birmingham | Phase 4 |
Pharmacology for OXYMETAZOLINE HYDROCHLORIDE
Drug Class | Vasoconstrictor |
Physiological Effect | Increased Sympathetic Activity Vasoconstriction |
Medical Subject Heading (MeSH) Categories for OXYMETAZOLINE HYDROCHLORIDE
Anatomical Therapeutic Chemical (ATC) Classes for OXYMETAZOLINE HYDROCHLORIDE
Paragraph IV (Patent) Challenges for OXYMETAZOLINE HYDROCHLORIDE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
RHOFADE | Topical Cream | oxymetazoline hydrochloride | 1% | 208552 | 1 | 2019-06-20 |
US Patents and Regulatory Information for OXYMETAZOLINE HYDROCHLORIDE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Rvl Pharms | UPNEEQ | oxymetazoline hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 212520-001 | Jul 8, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Rvl Pharms | UPNEEQ | oxymetazoline hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 212520-001 | Jul 8, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Rvl Pharms | UPNEEQ | oxymetazoline hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 212520-001 | Jul 8, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Mayne Pharma | RHOFADE | oxymetazoline hydrochloride | CREAM;TOPICAL | 208552-001 | Jan 18, 2017 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for OXYMETAZOLINE HYDROCHLORIDE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Mayne Pharma | RHOFADE | oxymetazoline hydrochloride | CREAM;TOPICAL | 208552-001 | Jan 18, 2017 | ⤷ Sign Up | ⤷ Sign Up |
Mayne Pharma | RHOFADE | oxymetazoline hydrochloride | CREAM;TOPICAL | 208552-001 | Jan 18, 2017 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for OXYMETAZOLINE HYDROCHLORIDE
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Australia | 2018229508 | Pharmaceutical cream compositions comprising oxymetazoline | ⤷ Sign Up |
Japan | 2014506927 | ⤷ Sign Up | |
World Intellectual Property Organization (WIPO) | 2015191917 | ⤷ Sign Up | |
World Intellectual Property Organization (WIPO) | 2012118704 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.